NASDAQ:MLND - Millendo Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.19 +0.82 (+7.91 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$11.19
Today's Range$10.0001 - $11.39
52-Week Range$6.77 - $17.40
Volume4,601 shs
Average Volume12,400 shs
Market Capitalization$133.92 million
P/E Ratio-0.57
Dividend YieldN/A
Beta3.06
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
Phone617-500-2802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$27.00 per share

Profitability

Net Income$-50,970,000.00
Net Margins-10,128.37%

Miscellaneous

Employees36
Market Cap$133.92 million
OptionableNot Optionable

Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Millendo Therapeutics.

What price target have analysts set for MLND?

2 Wall Street analysts have issued 12-month price targets for Millendo Therapeutics' shares. Their predictions range from $24.00 to $29.00. On average, they expect Millendo Therapeutics' share price to reach $26.50 in the next year. This suggests a possible upside of 136.8% from the stock's current price. View Analyst Price Targets for Millendo Therapeutics.

What is the consensus analysts' recommendation for Millendo Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Millendo Therapeutics.

Has Millendo Therapeutics been receiving favorable news coverage?

News stories about MLND stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Millendo Therapeutics earned a news impact score of 0.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a drop in short interest in December. As of December 14th, there was short interest totalling 70,452 shares, a drop of 93.5% from the November 30th total of 1,077,193 shares. Based on an average daily trading volume, of 15,848 shares, the days-to-cover ratio is currently 4.4 days. View Millendo Therapeutics' Current Options Chain.

Who are some of Millendo Therapeutics' key competitors?

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the folowing people:
  • Dr. Julia C. Owens Ph.D., Chief Exec. Officer, Pres and Director (Age 46)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Mr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)
  • Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)
  • Dr. Pharis Mohideen, Chief Medical Officer (Age 54)

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $11.19.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $133.92 million and generates $290,000.00 in revenue each year. The company earns $-50,970,000.00 in net income (profit) each year or ($19.79) on an earnings per share basis. Millendo Therapeutics employs 36 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is http://www.ovascience.com.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-500-2802 or via email at [email protected]


MarketBeat Community Rating for Millendo Therapeutics (NASDAQ MLND)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  29
MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote "Outperform" if you believe MLND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel